Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company

Bayer to Set Up Shenzhen Unit to Boost Women’s Healthcare in South China

Fineline Cube Oct 19, 2022

Bayer’s (ETR: BAYN) women’s healthcare unit for the South China region is reportedly planning to...

Company Drug

GenScript’s Legend Biotech Reports USD 55M in Carvykti Sales

Fineline Cube Oct 19, 2022

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that sales of...

Company Drug

YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval

Fineline Cube Oct 19, 2022

China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house...

Company Drug

Henlius Biotech’s Hanbeitai Gains NMPA Approval for Recurrent Glioblastoma

Fineline Cube Oct 19, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...

Company Policy / Regulatory

NHSA Responds to Proposal on Dental Implants’ Inclusion in NRDL

Fineline Cube Oct 19, 2022

The National Healthcare Security Administration (NHSA) has responded to the No. 6184 suggestion from the...

Company

Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance

Fineline Cube Oct 19, 2022

US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing...

Company Deals

Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion

Fineline Cube Oct 19, 2022

China-based Sichuan Biokin Pharmaceutical Co., Ltd is set to conduct an initial public offering (IPO)...

Company Drug

Mabwell Bioscience’s 9MW3011 Accepted for Review by China’s NMPA

Fineline Cube Oct 19, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that its clinical filing for...

Company Drug

Zhiyi Biotechnology Receives FDA Clearance for SK10 in Chemotherapy-Induced Diarrhea

Fineline Cube Oct 19, 2022

Guangzhou-based Zhiyi Biotechnology has announced receiving clearance from the US FDA for a clinical study...

Company Deals

Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion

Fineline Cube Oct 19, 2022

Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial...

Company Deals

Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy

Fineline Cube Oct 18, 2022

Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...

Company Drug

Abogen Biosciences Receives UAE Clinical Trial Approval for Omicron BA.4/5 mRNA Vaccine

Fineline Cube Oct 18, 2022

China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, has announced...

Company Deals

Shenzhen GeneBioHealth Secures USD 15M for Bio-Business Expansion

Fineline Cube Oct 18, 2022

Shenzhen GeneBioHealth Co., Ltd, a China-based in-vitro diagnostic (IVD) medical device developer, has reportedly raised...

Company Drug

CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute

Fineline Cube Oct 18, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National...

Company Drug

Gracell Biotechnologies Initiates Phase II Dosing for GC007g in B-ALL Patients

Fineline Cube Oct 18, 2022

China-based Gracell Biotechnologies Inc. has announced the first patient dosing in the Phase II portion...

Company Drug

Henlius Biotech Gains NMPA Approval for Phase I Trial of HLX60 in Solid Tumors and Lymphomas

Fineline Cube Oct 18, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical Products...

Company Deals

PureID Medical Technology Secures RMB 100M Series B Funding

Fineline Cube Oct 18, 2022

PureID Medical Technology Co., Ltd, a medical device compliance service provider based in Guangzhou, has...

Company Drug

Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results

Fineline Cube Oct 18, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a...

Company Drug

Jemincare’s Sonidegib Receives First Prescriptions in China for Basal Cell Carcinoma

Fineline Cube Oct 18, 2022

China-based Jiangxi Jemincare Group has announced the first prescriptions in China for its sonidegib, a...

Company Deals

Salus Biomed Raises Over RMB 100M in Pre-Series A Financing

Fineline Cube Oct 18, 2022

Salus Biomed, a sequencing and spatial omics platform provider based in Guangdong, has reportedly raised...

Posts pagination

1 … 665 666 667 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.